Skip to content
Parakho

Shilpa Medicare Ltd

NSE SHILPAMEDBSE 530549vbshilpa.comInvestor relations

Q1 FY27, unaudited

Revenue
₹189.04 Cr
Profit after tax
₹64.92 Cr

As filed with the exchange, standalone basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, standalone basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations189.04+104.52%597.03
Other income9.56−46.26%38.14
Total income198.60+80.18%635.17
Employee benefit expense34.17+23.43%110.99
Finance costs2.53+13.37%10.04
Depreciation & amortisation15.49+23.00%55.11
Total expenses151.05+67.35%506.46
Profit before tax51.06+245.35%148.13
Tax expense-13.86−134.43%15.16
Profit after tax64.92+213.66%132.97
Total comprehensive income64.92+213.66%132.86
Earnings per share
Earnings per share, basic₹3.32₹6.80
Earnings per share, diluted₹3.32₹6.80

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with NSE. Source

FY26 — from the company’s filing with NSE. Source

Earnings call

Q1 FY27

Shilpa Medicare reported its highest-ever quarterly revenue and EBITDA for the fourth consecutive quarter, with revenue of Rs 469 crores growing 43% year-on-year and EBITDA of Rs 139 crores growing 42% with a 30% margin. Management attributed the growth to the Formulation segment more than doubling, API growing 15%, and Biologics growing 42%, alongside a credit rating upgrade from A+ to AA-. Management also discussed multiple pipeline programs across API, Formulation and Biologics divisions, including oncology, biosimilars, and CDMO programs at various stages of development.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote. Read the cited summary

Earlier calls: Q4 FY26 · All quarters

Filings

12 shown · 44 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Page generated from filings held to 19 Aug 2026.